Neoplasms

All Conditions

Digestive System Diseases

Infections

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Adenoviridae Infections

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Hematinics

All Drugs and Chemicals

Anti-Infective Agents

Liver Extracts

Ganciclovir

Ganciclovir triphosphate

Antiviral Agents

Enzyme Inhibitors

Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.

ADV-TK

ganciclovir

Ding Ma, M.D.

HCC patients with tumors \>5 cm in diameter, regardless of involvement in the intrahepatic and extrahepatic portal branches participated in the study. Patients were randomized allocated in liver transplantation (LT) only group and LT plus ADV-TK therapy group. All patients received orthotopic liver transplantation; in the LT plus ADV-TK group, ADV-TK therapy was delivered to patients twice.

Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

Beijing YouAn Hospital

Huazhong University of Science and Technology

Director of the Laboratory of Tumor invasion and metastasis

patients received orthotopic LT and subsequent immunosuppression therapy

ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy

The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.

ADV-Tk

Orthotopic LT and subsequent immunosuppression therapy

Danhui Weng, Dr.

Ning Li, Dr

Jiahong Dong

Yunjin Zang

Qifa Ye

Lvnan Yan

Guihua Chen

Shusen Zheng

Jia Fan

Yongfeng Liu

Zhongyang Shen

Hao Wen

Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.

Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC

Multicenter Randomized Controlled Trial of Adenovirus-mediated Adjuvant Gene Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma

PFS was measured from the day of liver transplantation to objective recurrence (MRI or CT) or HCC-related death, whichever occurred first.

OS was measured from the day of liver transplantation to death.

TTP was the median period from the day of liver transplantation to objective recurrence (MRI or CT).

Director

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma	NCT02202564	Liver Cancer Hepatocellular ...	LT ADV-TK ganciclovir	18 Years - 70 Years	Huazhong University of Science and Technology
Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC	NCT03313596	Hepatocellular ...	ADV-Tk LT	18 Years - 65 Years	Huazhong University of Science and Technology
Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC	NCT03313596	Hepatocellular ...	ADV-Tk LT	18 Years - 65 Years	Huazhong University of Science and Technology
Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma	NCT02202564	Liver Cancer Hepatocellular ...	LT ADV-TK ganciclovir	18 Years - 70 Years	Huazhong University of Science and Technology

Spots Global Cancer Trial Database for lt

Every month we try and update this database with for lt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for lt

Every month we try and update this database with for lt cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for lt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.